Summary of Exelixis Conference Call Company Overview - **Company**: Exelixis - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Presenter**: Michael Morrissey, President and CEO Key Industry Insights - **Focus on Oncology**: Exelixis is dedicated to improving cancer treatment through innovative therapies, particularly in solid tumors, leveraging their expertise in biology, pharmacology, and clinical sciences [4][5][6] - **Franchise Building**: The company emphasizes building multiple blockbuster franchises rather than focusing on single indications, aiming to maximize value for patients and shareholders [4][6][30] Financial Performance - **2025 Preliminary Results**: - Total revenues: $2.32 billion - Net product revenues: $2.123 billion - R&D expenses: approximately $825 million - Cash at year-end: $1.65 billion [13][14] - **2026 Guidance**: - Net product revenue expected between $2.325 billion and $2.425 billion, with a midpoint of $2.375 billion - R&D expenses projected between $875 million and $925 million [14][15] Product Pipeline and Growth Strategy - **Cabozantinib (Cabo)**: - Continues to be the primary revenue driver, maintaining its position as the top TKI in the U.S. for renal cell carcinoma (RCC) [7][13] - Cumulative growth of 30% from 2023 to 2025 [13] - **Zanzalitinib (Zanza)**: - Aiming to establish Zanza as a significant oncology franchise, with ongoing pivotal trials in RCC, colorectal cancer (CRC), and neuroendocrine tumors (NET) [9][10][29] - First regulatory filing for CRC submitted in Q4 2025 [9][15] - **Pipeline Expansion**: - Four molecules currently in clinical trials, with plans for additional investigational new drug (IND) applications [10][12] Market Opportunities - **Colorectal Cancer (CRC)**: - Identified as a fragmented market with a $1.5 billion opportunity, with strategies to position Zanza effectively against competitors [32][33] - **Neuroendocrine Tumors (NET)**: - Projected market growth from $2.5 billion to over $7 billion, with a focus on innovative therapies [29] Strategic Approach - **Combination Therapies**: - Emphasis on developing combination therapies that leverage different mechanisms of action to enhance treatment efficacy [24][25][26] - **Market Leadership**: - Aiming to establish leadership in multiple tumor types, including RCC and CRC, while focusing on improving patient outcomes and standard of care [17][22] Shareholder Returns - **Capital Allocation**: - $2.16 billion returned to shareholders through share repurchase programs since March 2023, with an ongoing $750 million program [12][30] Conclusion - Exelixis is strategically positioned to leverage its strong product pipeline and market insights to drive growth in the oncology sector, focusing on building franchises that enhance patient care and deliver shareholder value. The company is committed to disciplined capital allocation and innovative research to maintain its competitive edge in the market [30][38]

Summary of Day One Biopharmaceuticals FY Conference Call Company Overview - **Company**: Day One Biopharmaceuticals (NasdaqGS:DAWN) - **Industry**: Biopharmaceuticals, focusing on treatments for pediatric patients with life-threatening diseases Key Points and Arguments Product Development and Pipeline - **Ojenda**: Over 1,000 children treated; positioned to become the standard of care for relapsed or refractory pediatric lobar glioma (PLGG) [3][4] - **Firefly-2 Trial**: Enrollment completion anticipated in the first half of 2026, aiming to expand Ojenda's use into frontline PLGG [3][19] - **Acquisition of Mersana**: Completed in Q4 2025, adding the Emmy Lee program to the portfolio, which is expected to contribute significantly to revenue [4][20] - **Day 301 Program**: Early clinical results are promising, with potential applications in multiple adult and pediatric indications [6][23] Financial Performance - **Cash Position**: Ended 2025 with over $440 million in cash and no debt, allowing for continued investment in high-potential programs [5] - **Revenue Growth**: - Q4 2025 net product revenue reached $52.8 million, a 37% increase from Q3 [12] - Full-year 2025 net product revenues totaled $155.4 million, up 172% year-over-year [12] - Guidance for 2026 net product revenue for Ojenda is projected at $225-$250 million [16] Market Dynamics - **Patient Population**: Approximately 1,100 treatment-eligible relapsed refractory PLGG patients annually [17] - **Market Expansion**: Anticipated EME approval in 2026 for global expansion, led by partner Ipsen [17] - **Physician Adoption**: Increasing confidence in multi-year treatments, contributing to growth in patient persistence and treatment duration [17][31] Clinical Data and Efficacy - **Ojenda's Efficacy**: - 19.4 months duration of response and 42.6 months median time to next treatment observed [10] - 75% of patients who took a drug holiday after 24 months remained treatment-free for 12 months [11] - **Emmy Lee Program**: Early evidence of monotherapy efficacy in adenoid cystic carcinoma (ACC), with a potential market opportunity of $300 million [20][21] Strategic Focus - **Dual Growth Model**: Combination of durable revenue from Ojenda and clinical catalysts from new programs like Emmy Lee and Day 301 [24] - **Commitment to Patients**: Focus on developing new medicines that significantly improve patient outcomes [24] Additional Important Content - **Payer Dynamics**: High reimbursement rates (over 90%) and favorable gross-to-net dynamics due to a significant percentage of Medicaid patients [37] - **Physician Education**: Increased efforts in educating physicians and caregivers to improve treatment management and patient outcomes [33][34] - **Future Updates**: Anticipated updates on Emmy Lee and Day 301 programs in mid to late 2026, with a focus on safety and efficacy data [43][44]

Terumo (OTCPK:TRUM.Y) FY Conference January 12, 2026 08:15 PM ET Company ParticipantsJin Hagimoto - CFOHikaru Samejima - CEOConference Call ParticipantsNone - AnalystOperatorGood evening. Thank you for joining us. I'm Naoki Sato from J.P. Morgan. Welcome to J.P. Morgan Healthcare Conference, Terumo's presentation. Again, it's my pleasure to be introducing Terumo. From the company, we have CEO Hikaru Samejima for the presentation, and after that, we'll have a Q&A session. With that, I will pass on to Mr. Sam ...

（来源：安庆新闻网） 转自：安庆新闻网 近日，省科技厅印发第四批安徽省"科技副总"名单。安庆师范大学副教授庞韬、董晓庆，皖南医学院讲 师丁秀敏等11人将在安庆科技型企业担任"科技副总"，涉及生物医药、功能膜新材料、刷业、生态农业 等多个领域。截至目前，共有63名省级"科技副总"在我市企业挂职。 "科技副总"是我省一项柔性引才政策，指从高校院所选派科研人才到企业兼任技术副总等职务，旨在为 企业直接注入创新动能，通过解决技术难题、转化科技成果，助力产业升级;同时构建了产学研深度融 合的桥梁，将人才智力资源精准输送到生产一线，有效提升了区域创新效率和整体竞争力，是推动地方 高质量发展的重要实践。 自该政策落地以来，我市常态化开展省级科技副总选派工作，打通高校院所科技人员到企业绿色通道， 同时建立定期调度机制，动态掌握"科技副总"服务企业情况，包括到企服务时长、人才联合引育、平台 共同建设、技术合作攻关、科技成果转化等工作内容，主动加强对接联络和服务保障，切实发挥好"科 技副总"的创新引领作用，加快创新链产业链人才链深度融合。 ...

（来源：内蒙古晨网） 转自：内蒙古晨网 细化用电管理，杜绝无效能耗。在用电方面，从细节抓起，实施全面管控。要求库区照明随日出日落时 间随时调整。严格执行夏季空调温度不低于26℃的规定，并强化办公纪律，要求下班后务必关闭电脑、 打印机等设备电源，彻底消除待机能耗。 为深入践行绿色低碳发展理念，推动库区可持续发展，2025年赤峰油库全员行动，聚焦水、电、暖三大 关键环节，扎实开展节能降耗工作。通过精细管理与技术创新相结合，取得显著的经济与环境效益。 深挖节水潜力，实现资源循环。赤峰油库大力倡导全员节约用水，同时提高水资源利用率，充分利用现 有油罐区污水收集池设施，在雨季高效收集雨水，经过处理后，100%用于库区绿化灌溉，替代原市政 供水或新鲜水源浇灌模式。此举不仅实现了雨水的资源化全量回收利用，更从源头显著压降了绿化养护 用水成本，水费同比下降34%，体现了从"末端管控"向"源头循环"管理模式的积极转变。 推行智慧供暖，按需精准供热。供暖季期间，建立动态调控机制，依据室外天气温度变化，科学合理调 控供暖温度，在保障工作环境舒适的前提下，有效避免了能源的过度消耗，实现了费用同比下降14%。 积少成多，聚沙成塔。20 ...

转自：内蒙古晨网 （来源：内蒙古晨网） 在自身发展的同时，公司积极践行社会责任，创新构建"龙头企业+合作社+牧户"合同制利益联结机 制，牵头组建产业化联合体，带动众多合作社、家庭牧场与牧民增收致富，为地方农牧业产业化发展注 入强劲动能。然而，缺乏传统抵押物的融资困境，一度成为企业扩大生产规模、升级加工技术的阻碍。 了解到企业需求后，农行锡林郭勒分行主动靠前、精准施策，打破传统抵押模式限制，创新推出冷冻肉 抵押贷款产品，成功为企业投放1000万元信贷资金。这笔"及时雨"般的金融支持，有效缓解了企业资金 周转压力，为其深化产业链条、提升加工产能、拓展市场空间提供了坚实保障，推动企业在规模化、标 准化、品牌化发展道路上稳步前行。 作为锡林郭勒盟畜产品加工产业的标杆力量，锡林郭勒盟威远畜产品有限责任公司的发展壮大之路，始 终离不开农行锡林郭勒分行的精准金融赋能。该行创新推出冷冻肉抵押贷款产品，以1000万元信贷资金 为企业破解融资难题，助力这家农业产业化国家重点龙头企业持续领跑区域农牧业产业化发展。 组建于2004年的锡林郭勒盟威远畜产品有限责任公司，是一家集活畜收购、肉食品加工、销售于一体的 股份制企业。公司硬件设 ...

国务院学位委员会近期印发的《"博士﹢硕士"双学位项目试点设置管理办法》（以下简称《办法》）是 我国高层次复合型人才培养机制的一次重要制度创新。该《办法》紧扣国家科技自立自强和产业转型升 级的战略需求，以"少而精、高起点、重交叉"为原则，对试点高校在学生遴选、培养方案设计、质量保 障等方面提出了明确要求。结合南通大学正在推进的学科交叉中心建设，以及我在机械工程、能源动力 工程学科的教学科研经验，谈几点看法与建议。 日前，国务院学位委员会正式印发了《"博士﹢硕士"双学位项目试点设置管理办法》（以下简称《办 法》）。政策一经出台便引发社会各界广泛关注。 "2023年以来，教育部推动部分高水平研究型大学试点建设学科交叉中心，积极开展高层次复合型人才 培养探索，部分高校通过完善课程体系、打造协同育人平台等方式，积极构建以项目为载体、以交叉融 合为特征的跨学科人才培养新模式，探索设置了'博士﹢硕士'双学位人才培养项目，为培养适应需求的 高层次复合型人才作出了有益尝试，取得了可复制的有益经验。"教育部学位管理与研究生教育司负责 人在介绍《办法》制定背景时如是指出。 有关负责人还表示，"博士﹢硕士"双学位项目试点设置工作坚持 ...

2026 年 1 月 13 日 招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 全球市场观察 全球市场观察 招银国际研究部 邮件：research@cmbi.com.hk | 环球主要股市上日表现 | | | | | --- | --- | --- | --- | | | 收市价 | | 升跌（%） | | | | 单日 | 年内 | | 恒生指数 | 26,608 | 1.44 | 3.82 | | 恒生国企 | 9,220 | 1.90 | 3.44 | | 恒生科技 | 5,863 | 3.10 | 6.29 | | 上证综指 | 4,165 | 1.09 | 4.95 | | 深证综指 | 2,715 | 2.05 | 7.25 | | 深圳创业板 | 3,388 | 1.82 | 5.78 | | 美国道琼斯 | 49,590 | 0.17 | 3.18 | | 美国标普 500 | 6,977 | 0.16 | 1.92 | | 美国纳斯达克 | 23,734 | 0.26 | 2.12 | | 德国 DAX | 25,405 | 0.57 | 3.74 | | 法国 CAC | 8, ...

每日港股評析 港股早晨快訊 2026 年 1 月 13 日星期二 2012-01- 17 市場回顧 中港股市短期展望 恒指短期阻力參考 27,188 點：聯儲局 12 月一如預期減息 0.25 厘，市場 預期 2026 年主席換屆後貨幣政策立場轉鴿，預測減息 2 次，高於聯儲局 預測，惟仍需觀望經濟數據及其餘委員取態。美國延續減息，內地放寬貨 幣政策的空間加大。2026 年為十五五規劃開局之年，市場預期內地第一 季政策發力，落實重點工作(擴內需、實現科技自主自強、反內卷)，並有 機會降準降息。中證監重申推動各類中長期資金進一步提高入市規模比 例，相對利好 A 股流動性。另一邊廂，港股對於全球流動性的變化更為敏 感，在地緣政治不穩下，外資或減慢流入；同時，北水自去年第四季以來 顯著減慢流入，港股上升動能不足，近月表現落後於 A 股，恒指短期料受 制 2025 年 11 月高位 27,188 點。 短期看好板塊 今日市場焦點 美國12月CPI、核心CPI及10月新屋銷售量； 宏觀焦點 工信部部長李樂成：將深入實施「人工智慧+製造」專項行動； 鮑威爾遭美司法部刑事調查，涉儲局翻新工程； 企業消息 小鵬汽車(9868 ...

| | 申银万国期货研究所 陆甲明 （从业编号F3079531 交易咨询号Z0015919） | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | lujm@sywgqh.com.cn 021-50583880 | | | | | | | | | LL PP | | | | | | | | | 1月 5月 9月 1月 5月 9月 | | | | | | | | | 前日收盘价 | 6506 | 6737 | 6772 | 6340 | 6560 | 6607 | | 期 | 前2日收盘价 | 6425 | 6674 | 6715 | 6302 | 6514 | 6563 | | 货 | 涨跌 | 81 | 63 | 57 | 38 | 46 | 44 | | 市 | 涨跌幅 | 1.26% | 0.94% | 0.85% | 0.60% | 0.71% | 0.67% | | 场 | 成交量 | 531 | 500823 | 35734 | 492 | 501126 | 42288 | | | 持仓量 | 7553 | 4907 ...